Theriva Biologics (TOVX) Research & Development (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Research & Development of $355000.0 for Q1 2026, down 88.04% year-over-year from $3.0 million in Q1 2025, and down 68.64% quarter-over-quarter from $1.1 million in Q4 2025.
Theriva Biologics (TOVX) Research & Development (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Research & Development for 17 consecutive years, with $355000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 88.04% year-over-year to $355000.0; the TTM figure through Mar 2026 stood at $6.0 million (down 48.09% YoY), while the FY2025 annual figure was $8.6 million, down 28.48% from the prior year.
- Research & Development retreated to $355000.0 in Q1 2026 per TOVX's latest filing, from $1.1 million in the prior quarter.
- Across five years, Research & Development topped out at $4.2 million in Q4 2023 and bottomed at $355000.0 in Q1 2026.
- Historically, Research & Development has averaged $2.8 million across 5 years, with a median of $3.0 million in 2024.
- Annual changes were most pronounced in 2022 — Research & Development soared 132.29% — and 2026, when it tumbled 88.04%.
- Theriva Biologics' Research & Development stood at $3.1 million in 2022, then jumped by 36.63% to $4.2 million in 2023, then tumbled by 31.22% to $2.9 million in 2024, then sank by 60.78% to $1.1 million in 2025, then slumped by 68.64% to $355000.0 in 2026.
- Business Quant data shows TOVX's Research & Development at $355000.0 in Q1 2026, $1.1 million in Q4 2025, and $2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 97.90 Mn |
| 10 | Theriva Biologics | 10.75 Mn | 10.75 Mn | - | 1.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.27 Mn |
| Mar 31, 2026 | 355,000.00 |
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 2.55 Mn |
| Jun 30, 2025 | 1.95 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | 2.89 Mn |
| Sep 30, 2024 | 2.73 Mn |
| Jun 30, 2024 | 2.95 Mn |
| Mar 31, 2024 | 3.46 Mn |
| Dec 31, 2023 | 4.20 Mn |
| Sep 30, 2023 | 4.01 Mn |
| Jun 30, 2023 | 3.13 Mn |
| Mar 31, 2023 | 2.98 Mn |
| Dec 31, 2022 | 3.07 Mn |
| Sep 30, 2022 | 2.57 Mn |
| Jun 30, 2022 | 3.49 Mn |
| Mar 31, 2022 | 2.60 Mn |
| Dec 31, 2021 | 2.78 Mn |
| Sep 30, 2021 | 1.97 Mn |